Compare IART & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | VSTM |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.9M | 1.1B |
| IPO Year | 1996 | 2011 |
| Metric | IART | VSTM |
|---|---|---|
| Price | $14.10 | $7.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $15.67 | ★ $17.22 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $0.55 | $248.46 |
| Revenue Next Year | $1.86 | $34.25 |
| P/E Ratio | $73.58 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $8.70 | $3.43 |
| 52 Week High | $20.49 | $10.82 |
| Indicator | IART | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 38.00 |
| Support Level | $11.96 | $7.72 |
| Resistance Level | $14.28 | $7.86 |
| Average True Range (ATR) | 0.78 | 0.56 |
| MACD | 0.20 | -0.24 |
| Stochastic Oscillator | 64.61 | 3.16 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.